Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase

By Ari Robicsek, J. Strahilevitz, G. Jacoby, M. Macielag, D. Abbanat, Chinsu Park, K. Bush, D. Hooper. Nature Medicine, 2006

1,010 citations recorded by the source corpus.

Subfields: Molecular Biology, Molecular Medicine, Pharmacology

View Paper: https://www.semanticscholar.org/paper/0fdbb487ec245c45feedfec702c049f8aab0ce65

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. L. Poirel
2. P. Nordmann
3. A. Carattoli
4. Xian-Zhi Li
5. H. Nikaido
6. J. Pitout
7. Gerard D. Wright
8. G. Jacoby

In Molecular Medicine

1. L. Poirel
2. P. Nordmann
3. J. Pitout
4. A. Carattoli
5. H. Nikaido
6. G. Jacoby
7. R. Cantón
8. Xian-Zhi Li

In Pharmacology

1. D. Hooper
2. Ari Robicsek
3. H. Nikaido
4. G. Jacoby
5. Xian-Zhi Li
6. P. Nordmann
7. L. Poirel
8. J. Pitout

Citations in the corpus

• Aminoglycosides: An Overview. (2016, background): “Last, a variant of AAC(60)-Ib that has acquired the ability to modify fluoroquinolones without significantly altering its activity against aminoglycosides has been identified in clinical isolates of Gram-negative bacteria (Robicsek et al. 2006; Strahilevitz et al. 2009).”
• Dissemination of Clonally Related Escherichia coli Strains Expressing Extended-Spectrum β-Lactamase CTX-M-15 (2008, methodology): “4-kb multidrug resistance region containing blaTEM-1, blaOXA-1, the aac(6′)-Ib-cr gene (aminoglycoside 6′-N-acetyltransferase type Ib-cr variant responsible for reduced susceptibility to both aminoglycosides and certain fl uoroquinolones), and genetic determinants coding for resistance to tetracycli”
• Prevalence in the United States of aac(6′)-Ib-cr Encoding a Ciprofloxacin-Modifying Enzyme (2006, background): “The diversity of plasmids on which this gene circulates is not yet known, but its presence as part of an integron cassette (1, 9) suggests that it could be widely mobile among plasmids.”
• Efflux-Mediated Drug Resistance in Bacteria: an Update (2009, background): “A variant of aminoglycoside-modifying enzyme, AAC(60)-Ib-cr, can also modify fluoroquinolones and thus yield fluoroquinolone resistance.([20]) Plasmid-mediated fluoroquinolone resistance due to the target protection (by qnr genes encoding proteins with a pentapeptide repeat) or efflux mechanism (by ”
• The antibiotic resistome: the nexus of chemical and genetic diversity (2007, background): “Hooper's group recently reported the remarkable evolution of an aminoglycoside acetyltransferase into a ciprofloxacin resistance enzym”
• Aminoglycoside Modifying Enzymes (2010, background): “…gram-negative clinical isolates (Vakulenko and Mobashery, 2003) and, as mentioned above, some of its variants show an extended spectrum including resistance to gentamicin [AAC(6′)-Ib11] (Casin et al., 2003) or reduced susceptibility to quinolones [AAC(6′)-Ib-cr] (Robicsek et al., 2006).”
• Nanotechnology as a therapeutic tool to combat microbial resistance. (2013, background): “This new gene codes for an N-acetyltransferse that acetylates an NH2 group of the fluoroquinolone molecule, thereby inactivating it [2,35,36].”
• Multidrug Resistance in Bacteria (2009, background): “Another example of new resistance mechanisms arising through mutations of prevalent resistance genes is a plasmid-coded ciprofloxacin resistance gene (18).”